Old Web
English
Sign In
Acemap
>
authorDetail
>
Hasumati Rahalkar
Hasumati Rahalkar
University of Hertfordshire
Biosimilar
Biological product
Emerging markets
Business
Accounting
4
Papers
14
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Current Regulatory Requirements for Biosimilars in Six Member Countries of BRICS-TM: Challenges and Opportunities.
2021
Frontiers of Medicine in China
Hasumati Rahalkar
Alan Sheppard
Gustavo Mendes Lima Santos
Chitralekha Dasgupta
Sonia Mayra Pérez-Tapia
Carlos A. López-Morales
Sam Salek
Show All
Source
Cite
Save
Citations (0)
Comparison of BRICS-TM Countries' Biosimilar Regulatory Frameworks With Australia, Canada and Switzerland: Benchmarking Best Practices.
2021
Frontiers in Pharmacology
Hasumati Rahalkar
Alan Sheppard
Sam Salek
Show All
Source
Cite
Save
Citations (1)
Challenges Faced by the Biopharmaceutical Industry in the Development and Marketing Authorization of Biosimilar Medicines in BRICS-TM Countries: An Exploratory Study
2021
Pharmaceutical medicine
Hasumati Rahalkar
Alan Sheppard
Carlos A. López-Morales
Luciano Lobo
Sam Salek
Show All
Source
Cite
Save
Citations (3)
Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines
2018
Frontiers in Pharmacology
Hasumati Rahalkar
Hacer Coskun Cetintas
Sam Salek
Show All
Source
Cite
Save
Citations (10)
1